Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 501

1.

Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure: Results From the DEFINE-HF and BIOSTAT-CHF Studies.

Grote Beverborg N, van der Wal HH, Klip IT, Anker SD, Cleland J, Dickstein K, van Veldhuisen DJ, Voors AA, van der Meer P.

JAMA Cardiol. 2019 Jun 12. doi: 10.1001/jamacardio.2019.1739. [Epub ahead of print]

PMID:
31188392
2.

Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure.

Felker GM, Borentain M, Cleland JG, DeSouza MM, Kessler PD, O'Connor CM, Seiffert D, Teerlink JR, Voors AA, McMurray JJV.

Eur J Heart Fail. 2019 Jun 6. doi: 10.1002/ejhf.1504. [Epub ahead of print]

PMID:
31168885
3.

Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.

Shah SJ, Voors AA, McMurray JJV, Kitzman DW, Viethen T, Bomfim Wirtz A, Huang E, Pap AF, Solomon SD.

JAMA. 2019 Jun 4;321(21):2101-2112. doi: 10.1001/jama.2019.6717.

PMID:
31162568
4.

Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology.

Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, de Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS, Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF, Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJS.

Eur J Heart Fail. 2019 May 26. doi: 10.1002/ejhf.1531. [Epub ahead of print]

PMID:
31129923
5.

Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?

Testani JM, Inzucchi SE, Voors AA.

Circulation. 2019 May 21;139(21):2383-2385. doi: 10.1161/CIRCULATIONAHA.119.038854. No abstract available.

PMID:
31107618
6.

Rationale and Design of the VITALITY-HFpEF Trial.

Butler J, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O'Connor CM, Pieske B, Ponikowski P, Shah SJ, Solomon SD, Voors AA, Wu Y, Carvalho F, Bamber L, Blaustein RO, Roessig L, Armstrong PW.

Circ Heart Fail. 2019 May;12(5):e005998. doi: 10.1161/CIRCHEARTFAILURE.119.005998.

PMID:
31096775
7.

Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure.

Emmens JE, Ter Maaten JM, Damman K, van Veldhuisen DJ, de Boer RA, Struck J, Bergmann A, Sama IE, Streng KW, Anker SD, Dickstein K, Lang CC, Metra M, Samani NJ, Ng LL, Voors AA.

Circ Heart Fail. 2019 May;12(5):e005544. doi: 10.1161/CIRCHEARTFAILURE.118.005544.

PMID:
31091993
8.

The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study.

Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, Devalaraja M, Anker SD, Cleland JG, Dickstein K, Filippatos GS, van der Harst P, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, Zannad F, Zwinderman AH, Hillege HL, van Veldhuisen DJ, Kakkar R, Voors AA, van der Meer P.

Eur J Heart Fail. 2019 May 14. doi: 10.1002/ejhf.1482. [Epub ahead of print]

PMID:
31087601
9.

Time to Revisit the Value of Urine Collections in Heart Failure.

Ter Maaten JM, Voors AA.

JACC Heart Fail. 2019 May;7(5):392-393. doi: 10.1016/j.jchf.2019.01.015. No abstract available.

PMID:
31047018
10.

Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF.

Grodin JL, Liebo MJ, Butler J, Metra M, Felker GM, Hernandez AF, Voors AA, McMurray JJ, Armstrong PW, O'Connor C, Starling RC, Troughton RW, Tang WHW.

J Card Fail. 2019 Apr 4. pii: S1071-9164(18)30979-5. doi: 10.1016/j.cardfail.2019.04.002. [Epub ahead of print]

PMID:
30953792
11.

Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure.

Ter Maaten JM, Kremer D, Demissei BG, Struck J, Bergmann A, Anker SD, Ng LL, Dickstein K, Metra M, Samani NJ, Romaine SPR, Cleland J, Girerd N, Lang CC, van Veldhuisen DJ, Voors AA.

Eur J Heart Fail. 2019 Jun;21(6):732-743. doi: 10.1002/ejhf.1437. Epub 2019 Mar 6.

PMID:
30843353
12.

Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation.

Mordi IR, Santema BT, Kloosterman M, Choy AM, Rienstra M, van Gelder I, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Metra M, Ng LL, Ouwerkerk W, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Voors AA, Lang CC.

Clin Res Cardiol. 2019 Jul;108(7):797-805. doi: 10.1007/s00392-018-1409-x. Epub 2019 Jan 4.

PMID:
30610382
13.

Rapid right-sided deterioration in heart failure with preserved ejection fraction.

Gorter TM, van Veldhuisen DJ, Voors AA.

Eur Heart J. 2019 Feb 21;40(8):699-702. doi: 10.1093/eurheartj/ehy900. No abstract available.

PMID:
30608519
14.

Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.

Beldhuis IE, Myhre PL, Claggett B, Damman K, Fang JC, Lewis EF, O'Meara E, Pitt B, Shah SJ, Voors AA, Pfeffer MA, Solomon SD, Desai AS.

JACC Heart Fail. 2019 Jan;7(1):25-32. doi: 10.1016/j.jchf.2018.10.017.

PMID:
30606484
15.

Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study.

Ferreira JP, Metra M, Anker SD, Dickstein K, Lang CC, Ng L, Samani NJ, Cleland JG, van Veldhuisen DJ, Voors AA, Zannad F.

Eur J Heart Fail. 2019 Feb;21(2):218-226. doi: 10.1002/ejhf.1380. Epub 2019 Jan 1.

PMID:
30600578
16.

Adrenomedullin in heart failure: pathophysiology and therapeutic application.

Voors AA, Kremer D, Geven C, Ter Maaten JM, Struck J, Bergmann A, Pickkers P, Metra M, Mebazaa A, Düngen HD, Butler J.

Eur J Heart Fail. 2019 Feb;21(2):163-171. doi: 10.1002/ejhf.1366. Epub 2018 Dec 28. Review.

PMID:
30592365
17.

Novel endotypes in heart failure: effects on guideline-directed medical therapy.

Tromp J, Ouwerkerk W, Demissei BG, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, van der Meer P.

Eur Heart J. 2018 Dec 21;39(48):4269-4276. doi: 10.1093/eurheartj/ehy712.

PMID:
30551207
18.

Discussion forum response to Canepa et al.

Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ.

Eur Heart J. 2019 Feb 21;40(8):705-706. doi: 10.1093/eurheartj/ehy796. No abstract available.

PMID:
30500882
19.

Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction.

Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, Filippatos G, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, van der Meer P, Voors AA.

Int J Cardiol. 2018 Nov 15;271:132-139. doi: 10.1016/j.ijcard.2018.04.001. Epub 2018 Jul 7.

20.

Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure.

Cao TH, Jones DJL, Quinn PA, Chan DCS, Hafid N, Parry HM, Mohan M, Sandhu JK, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Metra M, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, Lang CC, Ng LL.

Clin Proteomics. 2018 Nov 2;15:35. doi: 10.1186/s12014-018-9213-1. eCollection 2018.

21.

Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure (from BIOSTAT-CHF).

Suzuki T, Yazaki Y, Voors AA, Jones DJL, Chan DCS, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Lang CC, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Metra M, Ng LL.

Eur J Heart Fail. 2018 Oct 29. doi: 10.1002/ejhf.1338. [Epub ahead of print]

PMID:
30370976
22.

Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points.

Greene SJ, Hernandez AF, Sun JL, Butler J, Armstrong PW, Ezekowitz JA, Zannad F, Ferreira JP, Coles A, Metra M, Voors AA, Califf RM, O'Connor CM, Mentz RJ.

Circ Cardiovasc Qual Outcomes. 2018 Oct;11(10):e004783. doi: 10.1161/CIRCOUTCOMES.118.004783.

PMID:
30354576
23.

Treating oxidative stress in heart failure: past, present and future.

van der Pol A, van Gilst WH, Voors AA, van der Meer P.

Eur J Heart Fail. 2019 Apr;21(4):425-435. doi: 10.1002/ejhf.1320. Epub 2018 Oct 19. Review.

PMID:
30338885
24.

Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study.

Ferreira JP, Metra M, Mordi I, Gregson J, Ter Maaten JM, Tromp J, Anker SD, Dickstein K, Hillege HL, Ng LL, van Veldhuisen DJ, Lang CC, Voors AA, Zannad F.

Eur J Heart Fail. 2019 Jan;21(1):112-120. doi: 10.1002/ejhf.1323. Epub 2018 Oct 19.

PMID:
30338883
25.

Markers of left ventricular systolic dysfunction when left ventricular ejection fraction is normal.

Nauta JF, Jin X, Hummel YM, Voors AA.

Eur J Heart Fail. 2018 Dec;20(12):1636-1638. doi: 10.1002/ejhf.1326. Epub 2018 Oct 17. Review. No abstract available.

PMID:
30328663
26.

What is the added value of the waist-to-hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure? Reply.

Streng KW, Lang CC, Voors AA.

Eur J Heart Fail. 2019 Jan;21(1):132-133. doi: 10.1002/ejhf.1324. Epub 2018 Oct 8. No abstract available.

PMID:
30295977
27.

Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.

Voors AA, Shah SJ, Bax JJ, Butler J, Gheorghiade M, Hernandez AF, Kitzman DW, McMurray JJV, Wirtz AB, Lanius V, van der Laan M, Solomon SD.

Eur J Heart Fail. 2018 Nov;20(11):1601-1610. doi: 10.1002/ejhf.1295. Epub 2018 Sep 17.

PMID:
30225882
28.

Very Early Diuretic Response After Admission for Acute Heart Failure.

Kuroda S, Damman K, Ter Maaten JM, Voors AA, Okumura T, Kida K, Oishi S, Akiyama E, Suzuki S, Yamamoto M, Kitai T, Yoshida K, Matsumura A, Matsue Y.

J Card Fail. 2019 Jan;25(1):12-19. doi: 10.1016/j.cardfail.2018.09.004. Epub 2018 Sep 13.

PMID:
30219549
29.

Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF).

Fudim M, Parikh KS, Dunning A, DeVore AD, Mentz RJ, Schulte PJ, Armstrong PW, Ezekowitz JA, Tang WHW, McMurray JJV, Voors AA, Drazner MH, O'Connor CM, Hernandez AF, Patel CB.

Am J Cardiol. 2018 Nov 1;122(9):1506-1512. doi: 10.1016/j.amjcard.2018.07.023. Epub 2018 Aug 3.

PMID:
30172362
30.

Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction.

Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Lang CC, Ng LL, Zannad F, Zwinderman AH, Hillege HL, van der Meer P, Voors AA.

J Am Coll Cardiol. 2018 Sep 4;72(10):1081-1090. doi: 10.1016/j.jacc.2018.06.050.

PMID:
30165978
31.

Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction.

Santema BT, Kloosterman M, Van Gelder IC, Mordi I, Lang CC, Lam CSP, Anker SD, Cleland JG, Dickstein K, Filippatos G, Van der Harst P, Hillege HL, Ter Maaten JM, Metra M, Ng LL, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, Van der Meer P, Rienstra M, Voors AA.

Eur Heart J. 2018 Nov 14;39(43):3867-3875. doi: 10.1093/eurheartj/ehy421.

32.

Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production.

Du W, Piek A, Schouten EM, van de Kolk CWA, Mueller C, Mebazaa A, Voors AA, de Boer RA, Silljé HHW.

Theranostics. 2018 Jul 30;8(15):4155-4169. doi: 10.7150/thno.26055. eCollection 2018.

33.

A comparison of the prognostic value of BNP versus NT-proBNP after hospitalisation for heart failure.

Linssen GCM, Jaarsma T, Hillege HL, Voors AA, van Veldhuisen DJ.

Neth Heart J. 2018 Oct;26(10):486-492. doi: 10.1007/s12471-018-1145-x.

34.

OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction.

van der Pol A, Gil A, Tromp J, Silljé HHW, van Veldhuisen DJ, Voors AA, Hoendermis ES, Grote Beverborg N, Schouten EM, de Boer RA, Bischoff R, van der Meer P.

Cardiovasc Res. 2018 Dec 1;114(14):1871-1882. doi: 10.1093/cvr/cvy187.

PMID:
30032247
35.

Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial.

Grodin JL, Butler J, Metra M, Felker GM, Voors AA, McMurray JJ, Armstrong PW, Hernandez AF, O'Connor C, Starling RC, Tang WHW.

J Card Fail. 2018 Aug;24(8):512-519. doi: 10.1016/j.cardfail.2018.06.008.

PMID:
30012361
36.

Waist-to-hip ratio and mortality in heart failure.

Streng KW, Voors AA, Hillege HL, Anker SD, Cleland JG, Dickstein K, Filippatos G, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, van der Meer P, Lang CC.

Eur J Heart Fail. 2018 Sep;20(9):1269-1277. doi: 10.1002/ejhf.1244. Epub 2018 Jul 2.

37.

Bio-adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure.

Kremer D, Ter Maaten JM, Voors AA.

Eur J Heart Fail. 2018 Sep;20(9):1363-1365. doi: 10.1002/ejhf.1245. Epub 2018 Jun 22. No abstract available.

PMID:
29932477
38.

Heart failure with preserved ejection fraction: from mechanisms to therapies.

Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ.

Eur Heart J. 2018 Aug 7;39(30):2780-2792. doi: 10.1093/eurheartj/ehy301.

PMID:
29905796
40.

Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population.

Suthahar N, Meijers WC, Ho JE, Gansevoort RT, Voors AA, van der Meer P, Bakker SJL, Heymans S, van Empel V, Schroen B, van der Harst P, van Veldhuisen DJ, de Boer RA.

Eur J Heart Fail. 2018 Aug;20(8):1205-1214. doi: 10.1002/ejhf.1209. Epub 2018 Jun 1.

PMID:
29855124
41.

Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion: A Post Hoc Analysis of the PROTECT Data.

Metra M, Cotter G, Senger S, Edwards C, Cleland JG, Ponikowski P, Cursack GC, Milo O, Teerlink JR, Givertz MM, O'Connor CM, Dittrich HC, Bloomfield DM, Voors AA, Davison BA.

Circ Heart Fail. 2018 May;11(5):e004644. doi: 10.1161/CIRCHEARTFAILURE.117.004644.

PMID:
29748350
42.

Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure.

Rubio-Gracia J, Demissei BG, Ter Maaten JM, Cleland JG, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Givertz MM, Bloomfield DM, Dittrich H, Damman K, Pérez-Calvo JI, Voors AA.

Int J Cardiol. 2018 May 1;258:185-191. doi: 10.1016/j.ijcard.2018.01.067.

43.

Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial.

Cerbin LP, Ambrosy AP, Greene SJ, Armstrong PW, Butler J, Coles A, DeVore AD, Ezekowitz JA, Hernandez AF, Metra M, Starling RC, Tang W, Teerlink JR, Voors AA, Wu A, O'Connor CM, Mentz RJ.

JACC Heart Fail. 2018 Apr;6(4):298-307. doi: 10.1016/j.jchf.2018.01.018. Epub 2018 Mar 7.

44.

Risk stratification in acute heart failure: reply.

Demissei BG, Voors AA.

Eur J Heart Fail. 2018 May;20(5):945-947. doi: 10.1002/ejhf.1171. Epub 2018 Mar 7. No abstract available.

45.

Quantifying the HDL proteome by mass spectrometry: how many proteins truly associate with HDL? Reply.

Ng LL, Voors AA.

Eur J Heart Fail. 2018 Jun;20(6):1077-1078. doi: 10.1002/ejhf.1173. Epub 2018 Mar 2. No abstract available.

46.

Sense and Sensibility of the Use of NT-proBNP for Eligibility in Clinical Trials.

Voors AA.

JACC Heart Fail. 2018 Mar;6(3):257-259. doi: 10.1016/j.jchf.2018.01.003. Epub 2018 Feb 7. No abstract available.

47.

Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF.

Ouwerkerk W, Zwinderman AH, Ng LL, Demissei B, Hillege HL, Zannad F, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Ter Maaten JM, Lang CC, van der Harst P, Filippatos G, Dickstein K, Cleland JG, Anker SD, Voors AA.

J Am Coll Cardiol. 2018 Jan 30;71(4):386-398. doi: 10.1016/j.jacc.2017.11.041.

48.

Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients.

Grote Beverborg N, Klip IT, Meijers WC, Voors AA, Vegter EL, van der Wal HH, Swinkels DW, van Pelt J, Mulder AB, Bulstra SK, Vellenga E, Mariani MA, de Boer RA, van Veldhuisen DJ, van der Meer P.

Circ Heart Fail. 2018 Feb;11(2):e004519. doi: 10.1161/CIRCHEARTFAILURE.117.004519.

PMID:
29382661
49.

N-terminal pro-B-type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure.

Tromp J, Richards AM, Tay WT, Teng TK, Yeo PSD, Sim D, Jaufeerally F, Leong G, Ong HY, Ling LH, van Veldhuisen DJ, Jaarsma T, Voors AA, van der Meer P, de Boer RA, Lam CSP.

ESC Heart Fail. 2018 Apr;5(2):279-287. doi: 10.1002/ehf2.12252. Epub 2018 Jan 30.

50.

Heart failure with mid-range ejection fraction: causes and consequences.

Tromp J, Voors AA, Lam CSP.

Eur J Heart Fail. 2018 Apr;20(4):660-662. doi: 10.1002/ejhf.1134. Epub 2018 Jan 16. No abstract available.

Supplemental Content

Loading ...
Support Center